Timothy Shapiro is a Cardiology physician affiliated with Main Line Health. OpenAlex indexes 35 publications with 439 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
100 E Lancaster Ave
Jd Lankenau Pavilion, Mezzanine
Wynnewood, PA 190963450
Telephone
484-476-1000Registry record last updated 16 Oct 2015.
Industry payments
31 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20251 payment
- Boston Scientific CorporationProgram year202570 payments
- Novo Nordisk IncProgram year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
86.6%Statin22%Rosuvastatin Calcium47%Atorvastatin Calcium47%Simvastatin4%Pravastatin Sodium3%Part D≥306 patientsBeta blocker15.4%Metoprolol Succinate63%Carvedilol16%Metoprolol Tartrate8%Nebivolol Hcl6%Atenolol4%Bystolic1%Labetalol Hcl1%Sotalol1%Part D<11 patients+ 23 more classes in this area
Blood & clotting
9.6%Factor Xa inhibitor6.1%Eliquis72%Xarelto28%Part D≥121 patientsP2Y12 inhibitor3%Clopidogrel84%Brilinta11%Prasugrel Hcl5%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
3.6%SGLT2 inhibitor1.8%Farxiga62%Jardiance38%Part D≥26 patientsPotassium supplement1.5%Potassium Chloride77%Klor-Con M2023%Part D≥38 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- PROGNOSTIC IMPLICATIONS OF PLATELET FCγRIIA DURING THE FIRST YEAR AFTER MYOCARDIAL INFARCTION
Journal of the American College of Cardiology
2025 - Improving Management of Chest Pain with a High Sensitivity Troponin-Based Protocol
American Journal of Medical Quality
2025 - Midterm Clinical Outcomes of Robotic-Assisted Reverse Hybrid Coronary Revascularization: A Single-Center Experience
The American Journal of Cardiology
2024 - ASSOCIATION BETWEEN PROGNOSTIC IMPLICATIONS OF PLATELET FCγRIIA (PFCG) AND TREATMENT STRATEGY FOR MYOCARDIAL INFARCTION
Journal of the American College of Cardiology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Peter Kowey, MD
Main Line Health
William Gray, MD
Main Line Health
Scott Goldman, MD
Main Line Health
Linna Li, MD
Main Line Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”